Worried Dendreon looks to investors for $75M

With its prostate cancer drug Provenge hung up at the FDA, Dendreon has decided to drum up some additional cash with a $75 million convertible note offering. The company evidently needs the cash. The agency wants interim or final data from a late-stage study before it's willing to give the drug final approval. Some of the analysts have been voicing concerns that Dendreon may be unable to satisfy the FDA with interim data, as the agency sets the bar high for interim results. A convertible offering could get the company through any problems next year and on to final results.

- see Dendreon's release
- here's the report on Dendreon from Forbes

Related Articles:
Dendreon shares skyrocket on data deal. Report
Shareholders blast Dendreon. Report
Dendreon slashes jobs as it repositions. Report
FDA regulators question effectiveness of Provenge. Report

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.